

<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>SEVENTH SUPPLEMENTAL</b> <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)				ATTY. DOCKET NO. <b>210121.427C15</b>		APPLICATION NO. <b>09/593,793</b>	
				APPLICANTS <b>Jiangchun Xu et al.</b>			
				FILING DATE <b>June 13, 2000</b>		GROUP ART UNIT <b>1643</b>	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,818,707	04/04/89	Breneman	436	513	
	AB	6,261,562	07/17/01	Xu et al.	424	185.1	
	AC	6,262,245	07/17/01	Xu et al.	536	23.5	
	AD	6,329,505	12/11/01	Xu et al.	530	350	
	AE	6,350,452	02/26/02	Riss	424	185.1	
	AF	6,375,952	04/23/02	Koelle et al.	424	186.1	
	AG	6,620,922	09/16/03	Xu et al.	536	23.1	
	AH	6,800,746	10/05/04	Xu et al.	536	23.1	
	AI	6,943,236	09/13/05	Xu et al.	530	350	
	AJ	7,048,931	05/23/06	Xu et al.	424	192.1	
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
	AK	WO 99/67384	12/29/99	WIPO			
	AL	WO 00/61756	10/19/00	WIPO			
	AM	WO 01/34629	05/17/01	WIPO			
	AN	WO 01/73032	10/04/01	WIPO			
	AO	WO 01/81577	11/01/01	WIPO			
<b>OTHER ART</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	AP	Abbas, A.K. et al. (eds.), <i>Cellular and Molecular Immunology</i> , W.B. Saunders Company, Philadelphia, PA, 1991, pages 50-52.					
	AQ	Alberts, B. et al. (eds.), <i>Molecular Biology of The Cell</i> , Third Edition, Garland Publishing, Inc., New York, 1994, page 465.					
	AR	Anderson, L. et al., "A comparison of selected mRNA and protein abundances in human liver," <i>Electrophoresis</i> 18: 533-537, 1997.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							

<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>SEVENTH SUPPLEMENTAL</b> <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)				ATTY. DOCKET NO. <b>210121.427C15</b>		APPLICATION NO. <b>09/593,793</b>	
				APPLICANTS <b>Jiangchun Xu et al.</b>			
				FILING DATE <b>June 13, 2000</b>		GROUP ART UNIT <b>1643</b>	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA	2002/0022248	02/21/02	Xu et al.	435	69.1	
	BB	2002/0081680	06/27/02	Xu et al.	435	183	
	BC	2003/0185830	10/02/03	Xu et al.	424	155.1	
	BD	2005/0255519	11/17/05	Billing-Medel et al.	435	6	
	BE						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
	BF						
<b>OTHER ART</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	BG	Anderson, W. F., "Human gene therapy," <i>Nature</i> 392(Supp): 25-30, April 30, 1998.					
	BH	Blattman, J.N. et al., "Cancer Immunotherapy: A Treatment for the Masses," <i>Science</i> 305: 200-205, July 9, 2004.					
	BI	Bowie, J.U. et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," <i>Science</i> 247: 1306-1310, March 16, 1990.					
	BJ	Chen, Q. et al., "Development of Th1-type immune responses requires the type I cytokine receptor TCCR," <i>Nature</i> 407: 916-920, October 19, 2000.					
	BK	Corey, E. et al., "Prostate-specific antigen: characterization of epitopes by synthetic peptide mapping and inhibition studies," <i>Clinical Chemistry</i> 43 (4): 575-584, 1997.					
	BL	Correale, P. et al., "Generation of Human Cytolytic T Lymphocyte Lines Directed Against Prostate-Specific Antigen (PSA) Employing a PSA Oligopeptide Peptide," <i>Journal of Immunology</i> 161 (6): 3186-3194, September 15, 1998.					
	BM	Correale, P. et al., "In Vitro Generation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived From Prostate-Specific Antigen," <i>Journal of the National Cancer Institute</i> 89 (4): 293-300, February 19, 1997.					
	BN	Critical Synergy: The Biotechnology Industry and Intellectual Property Protection. Presentations of the Intellectual Property Committee of the Biotechnology Industry Organization at the October 17, 1994, Hearing of the U.S. Patent and Trademark Office, San Diego, CA, pages 75, 100-107.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>SEVENTH SUPPLEMENTAL</b> <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)				ATTY. DOCKET NO. <b>210121.427C15</b>		APPLICATION NO. <b>09/593,793</b>	
				APPLICANTS <b>Jiangchun Xu et al.</b>			
				FILING DATE <b>June 13, 2000</b>		GROUP ART UNIT <b>1643</b>	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY			TRANSLATION
							YES NO
	CB						
<b>OTHER ART</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	CC	Dillman, R.O., "Monoclonal Antibodies for Treating Cancer," <i>Annals of Internal Medicine</i> 111(7): 592-603, October 1, 1989.					
	CD	EMBL Database, Accession No. AA503963, July 4, 1997.					
	CE	Fu, L. et al., "Translational regulation of human p53 gene expression," <i>The EMBO Journal</i> 15: 4392-4401, 1996.					
	CF	Gao, C-L. et al., "Blinded Evaluation Of Reverse Transcriptase-Polymerase Chain Reaction Prostate-Specific Antigen Peripheral Blood Assay For Molecular Staging of Prostate Cancer," <i>Urology</i> 53(4): 714-721, 1999.					
	CG	GenBank Accession No. AA453562, June 5, 1997.					
	CH	GenBank Accession No. AB060851, June 13, 2001.					
	CI	GenBank Accession No. AB062977, June 13, 2001.					
	CJ	GenBank Accession No. BAB46871, June 13, 2001.					
	CK	GenBank Accession No. BAB60745, June 13, 2001.					
	CL	Genseq (Derwent) Accession No. AAU82643, April 23, 2002.					
	CM	Genseq (Derwent) Accession No. AAW71869, January 6, 1999.					
	CN	Genseq (Derwent) Accession No. AAW85068, February 12, 1999.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							

<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>SEVENTH SUPPLEMENTAL</b> <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)				ATTY. DOCKET NO. <b>210121.427C15</b>		APPLICATION NO. <b>09/593,793</b>	
				APPLICANTS <b>Jiangchun Xu et al.</b>			
				FILING DATE <b>June 13, 2000</b>		GROUP ART UNIT <b>1643</b>	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	DA						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY			TRANSLATION
							YES NO
	DB						
<b>OTHER ART</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	DC	Genseq (Derwent) Accession No. AAW85069, February 12, 1999.					
	DD	Genseq (Derwent) Accession No. ABB77575, August 30, 2002.					
	DE	Giri, D. et al., "Alterations in Expression of Basic Fibroblast Growth Factor (FGF) 2 and Its Receptor FGFR-1 in Human Prostate Cancer," <i>Clinical Cancer Research</i> 5: 1063-1071, May 1999.					
	DF	Gura, T., "Systems for Identifying New Drugs Are Often Faulty," <i>Science</i> 278: 1041-1042, November 7, 1997.					
	DG	Jain R.K., "Barriers to drug delivery in solid tumors," <i>Scientific American</i> 271(1):58-65, July 1994.					
	DH	Jansen, M. et al., "Translational Control of Gene Expression," <i>Pediatric Research</i> 37(6):681-686, 1995.					
	DI	Kajimoto, Y. et al., "cDNA Cloning and Tissue Distribution of a Rat Ubiquitin Carboxyl-Terminal Hydrolase PGP9.5," <i>J. Biochem.</i> 112: 28-32, 1992.					
	DJ	Kalos, M. et al., "Protein Expression Is Highly Restricted to Normal and Malignant Prostate Tissues," <i>The Prostate</i> 60: 246-256, 2004.					
	DK	McClellan, S. et al., "Evidence of Post-translational Regulation of P-Glycoprotein Associated with the Expression of a Distinctive Multiple Drug-resistant Phenotype in Chinese Hamster Ovary Cells," <i>Eur J Cancer</i> 29A(16): 2243-2248, 1993.					
	DL	Molecular Biology Reagents Catalog, USB, 1990.					
	DM	Ortega, S. et al., "Single-Step Purification on DEAE-Sephacel of Recombinant Polypeptides Produced in <i>Escherichia coli</i> ," <i>Biotechnology</i> 10: 795-798, July 1992.					
	DN	Parker, K.C. et al., "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains," <i>Journal of Immunology</i> 152: 163-175, January 1, 1994.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>SEVENTH SUPPLEMENTAL</b> <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)				ATTY. DOCKET NO. <b>210121.427C15</b>		APPLICATION NO. <b>09/593,793</b>	
				APPLICANTS <b>Jiangchun Xu et al.</b>			
				FILING DATE <b>June 13, 2000</b>		GROUP ART UNIT <b>1643</b>	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	EA						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY			TRANSLATION
							YES NO
	EB						
<b>OTHER ART</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	EC	Salgaller, M.L. et al., "Dendritic Cell-Based Immunotherapy of Prostate Cancer," <i>Critical Reviews in Immunology</i> 18 (1&2): 109-119, 1998.					
	ED	Shantz, L.M. et al., "Translational regulation of ornithine decarboxylase and other enzymes of the polyamine pathway," <i>The International Journal of Biochemistry and Cell Biology</i> 31: 107-122, 1999.					
	EE	Simmer, J.P. et al., "Purification, Characterization, and Cloning of Enamel Matrix Serine Proteinase 1," <i>J Dent Res</i> 77(2): 377-386, February 1998.					
	EF	Stedman's Medical Dictionary, 22nd Edition, The Williams & Wilkins Company, Baltimore, MD, pages 378 and 952.					
	EG	Stubbs, A.P. et al., "Differentially Expressed Genes in Hormone Refractory Prostate Cancer," <i>American Journal of Pathology</i> 154 (5): 1335-1343, May 1999.					
	EH	Tjoa, B.A. et al., "Follow-Up Evaluation of Prostate Cancer Patients Infused With Autologous Dendritic Cells Pulsed With PSMA Peptides," <i>The Prostate</i> 32: 272-278, 1997.					
	EI	Verma, I.M. et al., "Gene therapy-promises, problems and prospects," <i>Nature</i> 389: 239-242, September 18, 1997.					
	EJ	Weiner L.M., "An Overview of Monoclonal Antibody Therapy of Cancer," <i>Seminars in Oncology</i> 26(4)(Supp. 12): 41-50, August 1999.					
	EK	Xu, J. et al., "Identification and Characterization of Prostein, a Novel Prostate-specific Protein," <i>Cancer Research</i> 61: 1563-1568, February 15, 2001.					
	EL	Yokota, J. et al., "Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung," <i>Oncogene</i> 3: 471-475, 1988.					
	EM						
	EN						
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							